Alvotech (ALVO) Stock Price, Quote & News

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: www.alvotech.com

Address:

9, Rue de Bitbourg, Luxembourg, Luxembourg

Thestocktraderhubzee Jun. 25 at 9:52 AM

WATCHLIST JUN 25 2025 $LAES WISeSat And Astrocast Join Forces To Expand Secure Satellite Communications and Reinforce European Space Autonomy With Access To Astrocast's Nanosatellite Network $FFAI Faraday X Confirms FX Super One Debut At Invite-Only Los Angeles Event Featuring FF Stakeholders, Investors, Influencers, And Test Drive Experiences $ECX ECARX Signs Lidar Partnership With Global Robotic Lawn Mower Developer, Expanding Beyond Automotive Into AI-Driven Robotics $ALVO Alvotech, Kashiv, And Advanz Pharma Report Top Line Results For Xolair Biosimilar AVT23 In Confirmatory Efficacy Study $PONY Pony.ai Says It Is Added To Nasdaq Golden Dragon China Index On June 23 As Sole Autonomous Driving Firm

0 · Reply

Arbor_Vitae Jun. 25 at 8:29 AM

$ALVO news

0 · Reply

Thestocktraderhubzee Jun. 23 at 9:34 AM

WATCHLIST JUN 23 2025 $HIVE HIVE Digital Technologies To Acquire 7.2 MW Toronto Data Center, Paving The Way For BUZZ HPC's Sovereign AI Infrastructure In Canada $BASE Piper Sandler Downgrades Couchbase to Neutral, Raises Price Target to $24.5 $VMAR Vision Marine Acquires Nautical Ventures, Forming North America's First High-Voltage Electric Boat Manufacturer With Full Retail And Service Infrastructure $SNY Sanofi's Sarclisa Set To Expand Front-Line Multiple Myeloma Use In EU Following Positive CHMP Opinion Backed By MRD And PFS Gains $ALVO European Medicines Agency Recommends Approval Of Alvotech's AVT06, A Proposed Biosimilar To Eylea, For Eye Disorders Across Europe

0 · Reply

ZacksResearch Jun. 5 at 3:01 PM

$RDY teams up with $ALVO to tackle $MRK's Keytruda! 💊 The new collaboration aims to co-develop a biosimilar to Keytruda, Merck's cancer treatment powerhouse, which saw a 6% sales growth YoY, enhancing RDY's biosimilar portfolio in emerging markets and ALVO's global pipeline expansion. 📈 See the full potential of this deal here 👉 https://www.zacks.com/commentary/2485940/rdy-alvo-ink-collaboration-deal-for-mercks-keytruda-biosimilar?cid=sm-stocktwits-2-2485940-body&ADID=SYND_STOCKTWITS_TWEET_2_2485940_BODY

0 · Reply

Wallst45 Jun. 5 at 11:38 AM

Alvotech $ALVO and Dr. Reddy's $RDY team up to co-develop a biosimilar to Keytruda, aiming to enhance global cancer treatment options. The collaboration will leverage both companies' biosimilar expertise Bad news for $MRK

0 · Reply

clotho Jun. 4 at 6:01 PM

$ALVO and I’m out for now. https://ca.finance.yahoo.com/news/alvotech-intends-carry-private-placement-153200243.html

0 · Reply

Dake0001 Jun. 4 at 3:00 PM

$ALVO https://mfn.se/a/xbrane-biopharma/xbrane-biopharma-completes-sale-of-xb003-and-parts-of-its-organization-to-alvotech

0 · Reply

Dake0001 Jun. 2 at 8:55 PM

$ALVO https://www.globenewswire.com/news-release/2025/03/20/3045966/0/en/Alvotech-Acquires-Xbrane-s-R-D-Operations-in-Sweden-and-Further-Affirms-its-Global-Leadership-Position-in-Biosimilars-Development-and-Production.html

1 · Reply

clotho May. 29 at 6:10 AM

$ALVO I am guessing I’ll be speaking to myself on this board for a some time. I bought based on fundamentals. I rarely see success in this industry though.

1 · Reply

clotho May. 27 at 2:11 PM

$ALVO I started a position here based on some fundamentals. Now to monitor to determine if this will be a solid long position like I hope.

0 · Reply

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Jun 25, 2025, 4:45 PM EDT - 1 day ago

Main Results of 2025 Annual and Extraordinary General Meeting

Jun 25, 2025, 4:00 AM EDT - 2 days ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 25, 2025, 4:00 AM EDT - 2 days ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 23, 2025, 4:00 AM EDT - 4 days ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 23, 2025, 4:00 AM EDT - 4 days ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 11, 2025, 4:20 PM EDT - 15 days ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 11, 2025, 4:18 PM EDT - 15 days ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 6, 2025, 8:30 AM EDT - 20 days ago

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Jun 6, 2025, 8:30 AM EDT - 20 days ago

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

Jun 5, 2025, 1:56 PM EDT - 21 days ago

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

MRK RDY

Jun 4, 2025, 10:29 PM EDT - 22 days ago

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Jun 4, 2025, 11:32 AM EDT - 22 days ago

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

Jun 4, 2025, 7:45 AM EDT - 22 days ago

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Jun 2, 2025, 9:15 AM EDT - 24 days ago

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

May 28, 2025, 6:15 AM EDT - 4 weeks ago

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

May 26, 2025, 2:06 PM EDT - 4 weeks ago

Alvotech Annual General Meeting to be held June 25, 2025

May 23, 2025, 12:11 PM EDT - 4 weeks ago

Transactions of Managers and Closely Associated Persons

May 19, 2025, 3:15 AM EDT - 5 weeks ago

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

May 19, 2025, 2:30 AM EDT - 5 weeks ago

Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today

May 16, 2025, 1:52 PM EDT - 5 weeks ago

Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm

May 11, 2025, 1:08 AM EDT - 6 weeks ago

Alvotech (ALVO) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:30 AM EDT - 7 weeks ago

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

May 7, 2025, 4:45 PM EDT - 7 weeks ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 4:45 PM EDT - 7 weeks ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 5:00 AM EDT - 7 weeks ago

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025

May 2, 2025, 8:30 AM EDT - 7 weeks ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

May 2, 2025, 8:30 AM EDT - 7 weeks ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

Apr 30, 2025, 4:39 PM EDT - 2 months ago

Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade)

Mar 28, 2025, 5:01 PM EDT - 3 months ago

This Is a Test From GlobeNewswire

CMPS

Mar 27, 2025, 12:09 PM EDT - 3 months ago

Alvotech (ALVO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:30 AM EDT - 3 months ago

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Mar 26, 2025, 6:36 PM EDT - 3 months ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 6:34 PM EDT - 3 months ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 4:30 AM EDT - 3 months ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Mar 26, 2025, 4:30 AM EDT - 3 months ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Mar 20, 2025, 3:00 AM EDT - 3 months ago

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Mar 20, 2025, 3:00 AM EDT - 3 months ago

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Mar 7, 2025, 9:00 AM EST - 3 months ago

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Feb 24, 2025, 8:00 AM EST - 4 months ago

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Feb 21, 2025, 6:44 AM EST - 4 months ago

Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara

JNJ TEVA

Feb 21, 2025, 6:00 AM EST - 4 months ago

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Feb 18, 2025, 11:30 AM EST - 4 months ago

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

TEVA

Feb 18, 2025, 6:00 AM EST - 4 months ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Jan 27, 2025, 6:00 AM EST - 5 months ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Dec 23, 2024, 4:00 AM EST - 6 months ago

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Nov 21, 2024, 2:02 AM EST - 7 months ago

Alvotech's Position In The Coming Biosimilar Gold Rush

Nov 15, 2024, 8:00 AM EST - 7 months ago

Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors

Nov 14, 2024, 1:59 PM EST - 8 months ago

Alvotech (ALVO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:00 AM EST - 8 months ago

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024

Thestocktraderhubzee Jun. 25 at 9:52 AM

0 · Reply

Arbor_Vitae Jun. 25 at 8:29 AM

$ALVO news

0 · Reply

Thestocktraderhubzee Jun. 23 at 9:34 AM

0 · Reply

ZacksResearch Jun. 5 at 3:01 PM

0 · Reply

Wallst45 Jun. 5 at 11:38 AM

0 · Reply

clotho Jun. 4 at 6:01 PM

$ALVO and I’m out for now. https://ca.finance.yahoo.com/news/alvotech-intends-carry-private-placement-153200243.html

0 · Reply

Dake0001 Jun. 4 at 3:00 PM

$ALVO https://mfn.se/a/xbrane-biopharma/xbrane-biopharma-completes-sale-of-xb003-and-parts-of-its-organization-to-alvotech

0 · Reply

Dake0001 Jun. 2 at 8:55 PM

1 · Reply

clotho May. 29 at 6:10 AM

$ALVO I am guessing I’ll be speaking to myself on this board for a some time. I bought based on fundamentals. I rarely see success in this industry though.

1 · Reply

clotho May. 27 at 2:11 PM

$ALVO I started a position here based on some fundamentals. Now to monitor to determine if this will be a solid long position like I hope.

0 · Reply

killasimba May. 27 at 1:45 PM

$ALVO why up?

0 · Reply

StockDudeIndy May. 9 at 3:31 PM

$TEVA I’m in on Teva, but $ALVO looks like a stock that could really take off. Strong earnings report too.

0 · Reply

Zhezha May. 8 at 11:58 AM

$ALVO go up more

0 · Reply

OpenOutcrier May. 5 at 12:11 PM

$TEVA (+6.4% pre) Alvotech $ALVO and Teva (TEVA) Announce FDA Approval of Interchangeability for SELARSDI with Stelara - SI https://ooc.bz/l/63457

0 · Reply

DonCorleone77 May. 5 at 11:21 AM

$TEVA $ALVO Teva, Alvotech announce FDA approval of interchangeability for SELARSDI Teva Pharmaceuticals (TEVA), a U.S. affiliate of Teva Pharmaceutical Industries, and Alvotech (ALVO) announced that the U.S. Food and Drug Administration, FDA, has approved SELARSDI injection as interchangeable with the reference biologic Stelara. As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis. "The FDA's confirmation of full interchangeability for SELARSDI is an important development for patients and providers seeking to expand access to this important treatment," said Thomas Rainey, Senior Vice President, U.S. Biosimilars at Teva. "Teva's recent launch of two biosimilars - SELARSDI and EPYSQLI - coupled with a rich pipeline of assets expected to launch over the next few years, position Teva to establish a strong leadership position in the growing landscape of biosimilars and to drive growth for the company as it embarks on the next phase of its strategy."

0 · Reply

Lecock Apr. 3 at 3:42 PM

$ALVO So… No tariffs FOR NOW but Trump is planning to put tariffs on pharma

0 · Reply

Lecock Apr. 2 at 10:29 PM

$ALVO 10% tariffs on Iceland. What do you think about that?

1 · Reply

PenkeTrading Mar. 28 at 11:37 PM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Alvotech. Is that bullish or bearish? $ALVO #Alvotech #RsiOversold #NASDAQ

0 · Reply

Lecock Mar. 28 at 2:27 PM

$ALVO I can see this being sucessfull in the long run but why did the sentiment on stockwits turn from bearish to bullish all of a sudden?

0 · Reply

killasimba Mar. 28 at 10:19 AM

$ALVO why is this down so much?

1 · Reply

Kosmokrat Mar. 28 at 7:43 AM

$ALVO In their 2024 annual report they list $303 million "Finance Cost". Anybody knows what that actually means? Can't be just interest, right? It sounds an awful lot, if your total revenue is just $492M

1 · Reply

DEXWireNews Mar. 27 at 1:53 PM

📉 $ALVO down 5% post-earnings! Alvotech's 2024 revenue surged 426% to $491.98M, while net losses narrowed to $231.86M. Big growth, but the market isn’t buying—what’s next? 🤔 #Alvotech ⭐️ Learn More About $ALVO 📱Download our Mobile App » https://link-to.app/dexwirenews

0 · Reply

Market Cap	2.75B
Revenue (ttm)	489.68M
Net Income (ttm)	-231.86M
EPS (ttm)	N/A
PE Ratio	15.74
Forward PE	53.82
Profit Margin	-47.35%
Debt to Equity Ratio	-3.63

Volume	159,500
Avg Vol	208,660
Day's Range	N/A - N/A
Shares Out	301.48M
Stochastic %K	65%
Beta	0.19
Analysts	Sell
Price Target	$18.50